MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Alexion Pharmaceuticals (NASDAQ: ALXN)
Organization & Developments: Alexion
Parents
Alexion Pharmaceuticals (NASDAQ: ALXN)
Children
2016: Alexion - Sure, Buy The Dip. Now? - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2016: Alexion Tanks After CEO, CFO Unexpectedly Resign Amid Sales Probe _investors
2016: More bad news for Alexion: Soliris trial fails
2017: Alexion - Among The Best Risk/Reward In Biotech? - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2017: Alexion plots hundreds of layoffs, HQ move in sweeping corporate revamp
2017: Can Xencor Continue To Rally? - Xencor, Inc. (NASDAQ:XNCR)
2017: My Favorite Biotech Takeover Play - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2017: Waiting For A Pullback In Alexion Pharmaceuticals - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2018: Alexion Comes Roaring Back To Protect Its Key Drug Program - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2018: Alexion Passes Phase 3 Study, Looks To Expand On Rare Blood Disease Indication - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2018: Alexion Pharmaceuticals: A High Conviction, Large Cap Orphan Disease Pick For 2018 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2018: Alexion Pharmaceuticals: An Impressive Rare Disease Player At The End Of 2018_seekingalpha.com
2018: Alexion takes its first step rebuilding the pipeline, adding a rare disease drug, Wilson Therapeutics, in $855M cash buyout – Endpoints News
2018: Alexion's Ultomiris wins FDA approval_seekingalpha.com
2018: VA_65--Alexion Pharmaceuticals, Inc (65IB) 36F79718D0355 Contract Effective 4/1/2018 to 3/31/2018
2019: Alexion Pharmaceuticals: In The News And Moving Higher_seekingalpha.com
2019: Alexion's Complementary Growth Strategy - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
2019: Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals Nasdaq:FBIO
2020: Alexion Pharmaceuticals: Revising My Valuation_seekingalpha.com
2020: AstraZeneca to buy Alexion for $39 billion to expand in immunology
2020: This Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed_www.investors.com
Alexion Antibody Technologies
Alexion is working to get Soliris approved to treat other diseases, and is working in such areas as cancer treatment.
It’s profitable though it has only one drug on the market, Soliris (2011)
It’s the only drug on the market approved to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria.
PNH is a life-threatening, warranting a drug that can cost a patient $400,000 for full treatment.
Jumps
*Key People: Alexion
Finance & Acquisitions: Alexion